Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

2.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group.

Curr Med Res Opin. 2009 Oct;25(10):2361-71. doi: 10.1185/03007990903156111.

PMID:
19650752
5.

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

Pinelli NR, Cha R, Brown MB, Jaber LA.

Ann Pharmacother. 2008 Nov;42(11):1541-51. doi: 10.1345/aph.1L198. Epub 2008 Oct 28.

PMID:
18957626
6.

Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes.

Shand B, Scott R, Connolly S, Clarke R, Baker J, Elder P, Frampton C, Yeo J.

Diabetes Obes Metab. 2007 Jul;9(4):540-7.

PMID:
17587396
7.

Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.

Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, McCabe CH, Braunwald E; MERLIN-TIMI 36 Investigators.

Circulation. 2009 Apr 21;119(15):2032-9. doi: 10.1161/CIRCULATIONAHA.107.763912. Epub 2009 Apr 6.

11.

Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.

Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, Gylvin T, Kawamori R.

Clin Ther. 2009 Aug;31(8):1641-51. doi: 10.1016/j.clinthera.2009.08.011.

PMID:
19808125
12.

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.

Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators.

Curr Med Res Opin. 2009 Oct;25(10):2401-11. doi: 10.1185/03007990903178735.

PMID:
19650754
13.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
14.

A retrospective analysis of the fasting plasma glucose and glycosylated hemoglobin and pharmacotherapy change patterns among type 2 diabetes mellitus patients.

Davidson J, Koro C, Arondekar B, Lee BH, Fedder D.

Clin Ther. 2008 Feb;30(2):287-93. doi: 10.1016/j.clinthera.2008.02.007.

PMID:
18343267
15.

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.

Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group.

Diabetes Obes Metab. 2008 Sep;10(10):959-69. doi: 10.1111/j.1463-1326.2007.00839.x. Epub 2008 Jan 14.

PMID:
18201203
16.

Effect of pioglitazone therapy in lean type 1 diabetes mellitus.

Bhat R, Bhansali A, Bhadada S, Sialy R.

Diabetes Res Clin Pract. 2007 Dec;78(3):349-54. Epub 2007 May 31.

PMID:
17543413
17.

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.

Metabolism. 2008 Nov;57(11):1552-7. doi: 10.1016/j.metabol.2008.06.010.

PMID:
18940393
18.

Supplemental Content

Support Center